Where are the phase IIb results for Bimatoprost?

[Keki]

This doesn't explain why refuse to even mention bim scalp trial in every recent pdf, and we can forget a fast phase3 trial and the market release soon if they refuse to even release the results, if everything goes well for us they will release the trial results maybe at the end of the year, start another year trial, then wait for fda etc etc = at least early 2018, according to their february pdf aswell

[It's2014ComeOnAlready]

So clearly the science backs up the product and it definitely has a positive result on hair!

this seems like the only product out there with a legit ability to grow or reinforce your hair! and it's so close to market release(nothing is done phase IIb!)

could it be side effect problems? patent issues? timing?

it will be really unfortunate if they come out and say the results were good but not good enough to release, would be really unhappy about that as the science really supports this drug!

I caught some of Spencer's latest show, and Joe from SI called in. Bimatoprost was briefly mentioned, but Spencer made a very good point. He said that not releasing results may not have anything to do with good or bad, but only to do with business. There also may be a legal issue involved. My belief is, given that many other companies can legally manufacture bimatoprost, there may be a legal and business issue for them to release results prematurely, if it succeeded. There would also be a press-release, and likely news stories to follow. News would travel fast.

The investor relations person mentioned to BiqqieSmalls that the reason no results have been posted, is because of the "complexity of bimatoprost." That sounds like a legal, or business issue. I have a really hard time applying that same explanation to a failure. I'd say that explanation is quite simple - here are the results, they weren't sufficient enough for hair growth. No big deal, we're moving on with other successful products. No need to wait this long, no need for a press release, just results.

This is speculative, but I've always believed that Kythera's decision to move forward and start trials did have something to do with this drug succeeding. A phase 2b success would indicate the prostaglandin hypothesis having clinical proof of efficacy. Kythera's Chief Medical Officer worked at Allergan for 10 years, and could assuredly get information on that trial if they were planning on moving forward with something similar themselves. I'm sure he still has many ties to that company. After all, this is one of the first drugs being tested based on a "hypothesis." They must've needed many, many reasons to give them the will to move forward.

This drug does indeed work, but is it enough for them to produce? If it works, it would be amazing. It would be miracle grow for your hair, and unlike minox, it would work anywhere on the scalp. Unlike fin, it would actually regrow, and wouldn't have sexual side-effects.

rdawg, btw I included somewhere in the thread, the latest patent for bim that says the 3% range is perfect because it provides a surprisingly good balance between the wanted effects, without any unwanted side effects.

[rdawg]

So clearly the science backs up the product and it definitely has a positive result on hair!

this seems like the only product out there with a legit ability to grow or reinforce your hair! and it's so close to market release(nothing is done phase IIb!)

could it be side effect problems? patent issues? timing?

it will be really unfortunate if they come out and say the results were good but not good enough to release, would be really unhappy about that as the science really supports this drug!

[Keki]

Thx for the info, looked the q1 results aswell, they included Bimataprost SR Phase III recruiting US, Phase III initiation EU, 2015, no scalp phase 3 so i think it's a bad news... well at least for us, no info about the 25+ phase 3 projects...

If it's the same in q2 i don't think they will release any news, they will copy paste a similar presentation in q2 with no trial results, they don't even mentioned latisse in their earning... wtf, i miss the old allergan pipeline info, they now list only potential "milestone" and 0 info on secondary trials for their product

[BiqqieSmalls]

And it won't look like we'll get an answer soon.. But there is good news.

Research and Development head David Nicholson noted on the conference call earlier this week that Actavis had almost finished the rationalization of the companies' pipe lines and had decided to move forward with 70 projects. Some programs are still under review. I knew they wouldn't release results yet; this merger is so intricate. Also, keep in mind Bim was Allergan's product, not Actavis's...

When the Investor Relations told me 'a couple months', it sounds believable because Actavis will release Q2 earnings sometime in July.

[BiqqieSmalls]

biqquie no news from yesterday?

No news man

[Keki]

biqquie no news from yesterday?

[BiqqieSmalls]

I've been an investor in an unrelated biotech for a year or so now, and I've learned the hard way that companies definitely aren't obligated to release trial result information to investors. It's very frustrating sometimes, but that's the way it is.

I am pretty sure these companies have a fiduciary duty to provide you with information that will aid in your financial decisions.

[Justinian]

We know Bim works, we just don't know if it works well enough to be profitable over minox. The most likely scenario is they still don't know if they will continue on with bim for alopecia. Preliminary trials would seem to indicate that extremely low doses work to some extent, so it's just a question of how much does dose matter.

Also, I've been an investor in an unrelated biotech for a year or so now, and I've learned the hard way that companies definitely aren't obligated to release trial result information to investors. It's very frustrating sometimes, but that's the way it is.

[Keki]

Well your conclusions are wrong, prostaglanding analog works, to some people even little dose like 0.01 let hairs grows like crazy with documented pics made from docs and not aneddoctal bullshit like 95% of posts here, they can be a solution to people who cannot use minox or fin or where those treatment didn't give good results, we can discuss if can be a good product for the market even if the % of people responding to treatment are inferior to minox, or we can discuss if the cost for the 3% solution is too high for consumers but we cannot say "this doesn't work" becaose that's a lie

[StayThick]

Then you don't understand the meaning of a rhetorical question. Moving on.

Your anger is misguided. Came across to me as a legit question versus a rhetorical one. In which case, I gave you an answer. My sincere apologies if your question was made with a hint of sarcasm. I didn't see a point in your question...

Continue wasting time on a eye lash drug that won't make it to market and if it does is miles away from reaching actual product to your bald head. You don't even know the results of this for hairloss let alone when/if it will come to fruition.

Get mad at the lack of hairloss treatments that causes you to make such retarded rhetorical questions. There isn't a solution outside of minox/fin. Deal with it. I am.

[BiqqieSmalls]

I listened to the conference call this morning and was actually registered to ask a question, but they only took about 10 questions from different investors. Nothing was asked about Bim for MPB because I don't think people know about it. It was in Allergan's pipeline, not Actavis's. Could this be why Actavis is not talking about it?

I have sent an email to the VP of Investor Relations earlier today. Haven't yet received a response. I'll call her tomorrow to discuss this.

[joel203]

And I provided you an answer to that rhetorical question. "NO." Move on.

*facepalm*

[It's2014ComeOnAlready]

And I provided you an answer to that rhetorical question. "NO." Move on.

Then you don't understand the meaning of a rhetorical question. Moving on.

[StayThick]

That was a rhetorical question

And I provided you an answer to that rhetorical question. "NO." Move on.